William Greene
Chief Executive Officer at Iconic Therapeutics, Inc.
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Peter Diamandis | M | 62 |
Fountain Therapeutics, Inc.
 Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | 6 years |
| Thomas Rando | M | - |
Fountain Therapeutics, Inc.
Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | - |
| Kirk Dornbush | M | - |
Iconic Therapeutics, Inc.
 Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 21 years |
| James Scibetta | M | 59 |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 7 years |
| Robert DuBridge | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 8 years |
| Sangeeta Bhatia | M | 55 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Michael Batalia | M | - |
Wake Forest University
| - |
| Matthew S. Cullinan | M | - |
Wake Forest University
| - |
| Stephen R. Berlin | M | - |
Wake Forest University
| - |
| Louis Kucera | M | - |
Wake Forest University
| 54 years |
| Saud Al-Bawardi | M | 48 |
Hevolution Foundation
| - |
| Roger Beahm | M | - |
Wake Forest University
| - |
| David N. LaMond | M | - |
Wake Forest University
| - |
| Detlev Biniszkiewicz | M | 56 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Yury Kukushkin | M | - |
Hevolution Foundation
| 1 years |
| Boris Pasche | M | 63 |
Wake Forest University
| - |
| Darryl L. Landis | M | - |
Wake Forest University
| - |
| Ron Burkle | M | 70 |
Hevolution Foundation
| - |
| Khanna Khanna | M | - |
Fountain Therapeutics, Inc.
Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | - |
| Mehmood Khan | M | 66 |
Hevolution Foundation
| 4 years |
| Stan Meiburg | M | - |
Wake Forest University
| - |
| Saleh Al-Qahtani | M | - |
Hevolution Foundation
| - |
| Munir Eldesouki | M | - |
Hevolution Foundation
| - |
| Fahd Al-Rasheed | M | - |
Hevolution Foundation
| - |
| Fahad Toonsi | M | - |
Hevolution Foundation
| - |
| Yasir Al-Rumayyan | M | - |
Hevolution Foundation
| - |
| Mohammed Al-Saud | M | - |
Hevolution Foundation
| - |
| Ibrahim AlSuwaiyel | M | - |
Hevolution Foundation
| - |
| Martin Guthold | M | - |
Wake Forest University
| - |
| Michael Martin | M | - |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Elizabeth Domenech | F | - |
Wake Forest University
| - |
| Lisbeth Evans | F | - |
Wake Forest University
| - |
| Janice Calloway | F | - |
Wake Forest University
| - |
| Louise Broyhill | F | - |
Wake Forest University
| - |
| James Becton | M | - |
Wake Forest University
| - |
| Greg Keeley | M | - |
Wake Forest University
| - |
| Dirk Sauer | M | 64 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 3 years |
| Jane Brightwell | F | - |
Wake Forest University
| - |
| Elizabeth Amato | F | 67 |
Wake Forest University
| - |
| Brig Sorber | M | - |
Wake Forest University
| - |
| Mark Leuchtenberger | M | 67 |
Wake Forest University
| - |
| William G. Ward | M | 70 |
Wake Forest University
| - |
| Eric Wiseman | M | 68 |
Wake Forest University
| - |
| Matthew King | M | 65 |
Wake Forest University
| - |
| Julia Gregory | F | 71 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 7 years |
| Scott E. Reed | M | 75 |
Wake Forest University
| - |
| David W. Dupree | M | 71 |
Wake Forest University
| - |
| H. Culp | M | 60 |
Wake Forest University
| - |
| Thomas W. Bunn | M | 71 |
Wake Forest University
| 14 years |
| Ronald E. Deal | M | 80 |
Wake Forest University
| 21 years |
| William L. Marks | M | 80 |
Wake Forest University
| - |
| Curtis Farmer | M | 61 |
Wake Forest University
| - |
| Bruce Robertson | M | 61 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 10 years |
| Dan Hicklin | M | 61 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | - |
| Adelaide Sink | F | 75 |
Wake Forest University
| - |
| Andrew J. Schindler | M | 79 |
Wake Forest University
| - |
| Todd Foley | M | 52 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 10 years |
| Jack Lowden | M | 66 |
Wake Forest University
| - |
| Harold Rosser | M | 75 |
Wake Forest University
| - |
| Patrick Thean | M | - |
Wake Forest University
| - |
| Troy McConnell | M | - |
Wake Forest University
| - |
| Kim Westmoreland | M | - |
Wake Forest University
| - |
| Charles Iacovou | M | - |
Wake Forest University
| - |
| Elizabeth J. Gatewood | M | - |
Wake Forest University
| 20 years |
| Stephen L. Wallenhaupt | M | - |
Wake Forest University
| - |
| Peter Carlson | M | 60 |
Wake Forest University
| - |
| Daniel M. Delen | M | 58 |
Wake Forest University
| - |
| Andrew Liveris | M | 69 |
Hevolution Foundation
| - |
| Ashish Khanna | M | 52 |
Fountain Therapeutics, Inc.
Fountain Therapeutics, Inc. BiotechnologyHealth Technology Fountain Therapeutics, Inc. develops treatment for aging-associated diseases. The company is headquartered in San Francisco, CA. | - |
| C. Nye | M | 61 |
Wake Forest University
| - |
| Mitesh B. Shah | M | 54 |
Wake Forest University
| - |
| Bruce A. Cohen | M | 71 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | - |
| Lars Nelson | M | 65 |
Wake Forest University
| - |
| K. Hirth | M | 72 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 9 years |
| Donald C. Ingram | M | - |
Wake Forest University
| - |
| Evgeny Lebedev | M | - |
Hevolution Foundation
| - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Lori Kunkel | M | 66 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 6 years |
| Carl Johan Kördel | M | 62 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | - |
| Kathryn Corzo | F | 63 |
Maverick Therapeutics, Inc.
Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | 1 years |
| Brandon Smith | M | 50 |
Iconic Therapeutics, Inc.
Iconic Therapeutics, Inc. BiotechnologyHealth Technology Iconic Therapeutics, Inc. engages in the development of novel therapeutics for the treatment of serious eye disorders. Its product ICON-1, is a novel immune-conjugate fusion protein that works with the body’s immune system to address the root causes of inflammation and angiogenesis together, potentially altering the course of causes of blindness. The company was founded by Alan Garen, Kirk Dornbush, and Michael I. Sherman in 2003 and is headquartered in South San Francisco, CA. | 3 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 67 | 83.75% |
| Saudi Arabia | 13 | 16.25% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- William Greene
- Personal Network
